34443-04-4

Basic information

• Product Name: N-(4-hydroxyphenyl)acrylamide
• Synonyms: N-(4-hydroxyphenyl)acrylamide;N-(4-Hydroxyphenyl)propenamide
• CAS NO: 34443-04-4
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.17326
• EINECS: 252-026-9
• Mol File: 34443-04-4.mol

Chemical Properties

• Boiling Point: 385.9°Cat760mmHg
• Flash Point: 187.2°C
• Appearance: /
• Density: 1.231g/cm³
• Vapor Pressure: 1.65E-06mmHg at 25°C
• Refractive Index: 1.623
• PKA: 10.03±0.26(Predicted)
• CAS DataBase Reference: N-(4-hydroxyphenyl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-hydroxyphenyl)acrylamide(34443-04-4)
• EPA Substance Registry System: N-(4-hydroxyphenyl)acrylamide(34443-04-4)

Safety Data

• Hazardous Substances Data: 34443-04-4(Hazardous Substances Data)

Usage

Uses

Used in Polymer Production:
N-(4-hydroxyphenyl)acrylamide is utilized as a monomer in the synthesis of polymers, contributing to the development of materials with enhanced properties such as stability and reactivity.
Used in Adhesives:
In the adhesives industry, N-(4-hydroxyphenyl)acrylamide is employed as a component to improve the bonding strength and durability of adhesive formulations.
Used in Coatings:
N-(4-hydroxyphenyl)acrylamide is also used in the production of coatings, where it helps in creating coatings with better adhesion, resistance, and longevity.
Used as a Reagent in Organic Synthesis:
N-(4-hydroxyphenyl)acrylamide serves as a reagent in various organic synthesis processes, facilitating the creation of a range of chemical products.
Used as a Precursor in Pharmaceutical Compound Preparation:
In the pharmaceutical industry, N-(4-hydroxyphenyl)acrylamide is used as a precursor for the preparation of different pharmaceutical compounds, leveraging its antioxidant properties for potential therapeutic applications.

InChI:InChI=1/C9H9NO2/c1-2-9(12)10-7-3-5-8(11)6-4-7/h2-6,11H,1H2,(H,10,12)

Upstream product

• 123-30-8 4-amino-phenol 
• 79-10-7 acrylic acid 
• 814-68-6 acryloyl chloride 

Downstream Products

• 104374-07-4 N-(4-Hydroxy-phenyl)-3-(4-pyridin-2-yl-piperazin-1-yl)-propionamide 
• 72224-49-8 N-(4-hydroxy-phenyl)-3-(4-phenyl-piperazin-1-yl)-propionamide 
• 1603827-85-5 C₃₄H₄₇N₃O₁₀ 
• 1603827-86-6 C₃₀H₃₉N₃O₁₀ 
• 1603827-88-8 C₃₄H₄₈N₄O₉ 
• 1603827-89-9 C₃₄H₄₇N₄O₁₂S^(1-)*Na⁽¹⁺⁾ 
• 1603827-79-7 C₂₆H₃₅N₃O₄ 
• 1674370-85-4 C₃₃H₄₅N₃O₁₀ 
• 1604244-23-6 C₃₃H₄₅N₃O₁₃S 
• 1604244-24-7 C₃₄H₄₈N₄O₁₂S 
• 1603827-80-0 C₂₄H₃₁N₃O₄ 
• 1603827-81-1 C₂₇H₃₇N₃O₄ 
• 1603827-82-2 C₃₇H₄₇N₃O₁₃ 
• 1603827-83-3 C₄₀H₅₃N₃O₁₃ 

Relevant articles and documents

Improved reagents for newborn screening of mucopolysaccharidosis types I, II, and VI by tandem mass spectrometry

Tandem mass spectrometry for the multiplex and quantitative analysis of enzyme activities in dried blood spots on newborn screening cards has emerged as a powerful technique for early assessment of lysosomal storage diseases. Here we report the design and process-scale synthesis of substrates for the enzymes α-l-iduronidase, iduronate-2-sulfatase, and N-acetylgalactosamine-4- sulfatase that are used for newborn screening of mucopolysaccharidosis types I, II, and VI. The products contain a bisamide unit that is hypothesized to readily protonate in the gas phase, which improves detection sensitivity by tandem mass spectrometry. The products contain a benzoyl group, which provides a useful site for inexpensive deuteration, thus facilitating the preparation of internal standards for the accurate quantification of enzymatic products. Finally, the reagents are designed with ease of synthesis in mind, thus permitting scale-up preparation to support worldwide newborn screening of lysosomal storage diseases. The new reagents provide the most sensitive assay for the three lysosomal enzymes reported to date as shown by their performance in reactions using dried blood spots as the enzyme source. Also, the ratio of assay signal to that measured in the absence of blood (background) is superior to all previously reported mucopolysaccharidosis types I, II, and VI assays.

Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor

Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions. A series of retinoid analogues were synthesized and examined for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. A number inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development. Shortening the chain length of the FEN derivative substantially abolished binding to sRBP, indicating that the strength of the interaction lies in the polyene chain region. Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compounds on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.

COMPOSITIONS AND METHODS FOR DETECTION OF LYSOSOMAL STORAGE DISEASE

The present invention provides compositions for performing assays of enzyme activity associated with lysosomal storage diseases. The invention further provides methods for determining enzyme activity, and methods for the screening for lysosomal storage disease in an individual.